Table 4 Multivariable analysis of factors associated with overall pathologic complete response among TNBC patients
Characteristic | Univariate analysis | Multivariable analysis | |||
|---|---|---|---|---|---|
No pCR n = 278 | pCR n = 133 | p | Odds ratio (95% CI) | p | |
Age | 52 (44–60) | 47 (36–56) | <0.001 | 0.97 (0.95, 1.00) | 0.024 |
Race | 0.12 | ||||
Black | 61 (75%) | 20 (25%) | |||
Asian, Native American, or other | 42 (61%) | 27 (39%) | |||
White | 144 (64%) | 80 (36%) | |||
Unknown | 31 | 6 | |||
Clinical T stage | 0.2 | ||||
T1 | 33 (56%) | 26 (44%) | |||
T2 | 165 (70%) | 70 (30%) | |||
T3 | 60 (72%) | 23 (28%) | |||
T4 | 19 (66%) | 10 (34%) | |||
Unknown | 1 | 4 | |||
BRCA status | 0.013 | ||||
Noncarrier | 226 (71%) | 91 (29%) | ref. | ref. | |
BRCA1 | 36 (54%) | 31 (46%) | 1.66 (0.81, 3.36) | 0.2 | |
BRCA2 | 16 (59%) | 11 (41%) | 1.97 (0.71–5.17) | 0.2 | |
Differentiation | 0.062 | ||||
Poor | 242 (66%) | 124 (34%) | |||
Well/moderate | 33 (80%) | 8 (20%) | |||
Unknown | 3 | 1 | |||
Histology | 0.07 | ||||
Ductal | 264 (69%) | 121 (31%) | |||
Lobular/mixed | 13 (65%) | 7 (35%) | |||
Unknown | 1 | 5 | |||
Neoadjuvant regimen | 0.15 | ||||
ACT-based | 263 (67%) | 130 (33%) | |||
Taxane, platinum, or CMF | 15 (83%) | 3 (17%) | |||
Carboplatin | 73 (68%) | 37 (32%) | <0.001 | ||
Lymphovascular invasion | 81 (85%) | 14 (15%) | <0.001 | 0.44 (0.22–0.83) | 0.014 |
Unknown | 52 | 56 | |||
